anastrozole has been researched along with Obesity in 13 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Testosterone (T) administration to men increases T, estradiol (E2), dihydrotestosterone (DHT), and fat-free mass (FFM), and decreases fat mass (FM) but does not consistently improve insulin sensitivity (IS)." | 9.19 | Testosterone with dutasteride, but not anastrazole, improves insulin sensitivity in young obese men: a randomized controlled trial. ( Allehmazedeh, K; Coviello, AD; Herbst, KL; Juang, PS; Peng, S; Shah, A, 2014) |
| "This is a preliminary study investigating the efficacy of aromatase inhibitor anastrozole in treating endometrial hyperplasia in obese postmenopausal women." | 9.11 | Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women. ( Agorastos, T; Bontis, JN; Efstathiadis, E; Pantazis, K; Vaitsi, V; Vavilis, D, 2005) |
| "We determined gonadotropin-, estradiol- and anastrozole- serum concentrations from postmenopausal, early stage breast cancer patients receiving upfront anastrozole within routine after care." | 7.85 | Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole? ( Beer, B; Czech, T; Daniaux, M; Holzner, B; Hubalek, M; Kemmler, G; Meraner, V; Oberacher, H; Oberguggenberger, A; Sperner-Unterweger, B; Sztankay, M; Weigel, G; Wildt, L, 2017) |
| "Estradiol concentrations in postmenopausal women with early, ER-positive breast cancer on anastrozole were significantly different in normal weight versus overweight or obese patients at baseline, but not at 12 and 24 months." | 7.80 | Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole. ( Bauer, T; Hadji, P; Hars, O; Knöll, D; Kyvernitakis, I; Struck, M, 2014) |
| "A total of 216 postmenopausal patients with early-stage breast cancer who were receiving AI treatment with anastrozole constituted the final sample included in the analysis." | 7.80 | Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels. ( Beer, B; Giesinger, J; Holzner, B; Hubalek, M; Kemmler, G; Meraner, V; Oberacher, H; Oberguggenberger, A; Schubert, B; Seeber, B; Sperner-Unterweger, B; Sztankay, M; Wildt, L, 2014) |
| "Testosterone (T) administration to men increases T, estradiol (E2), dihydrotestosterone (DHT), and fat-free mass (FFM), and decreases fat mass (FM) but does not consistently improve insulin sensitivity (IS)." | 5.19 | Testosterone with dutasteride, but not anastrazole, improves insulin sensitivity in young obese men: a randomized controlled trial. ( Allehmazedeh, K; Coviello, AD; Herbst, KL; Juang, PS; Peng, S; Shah, A, 2014) |
| "This is a preliminary study investigating the efficacy of aromatase inhibitor anastrozole in treating endometrial hyperplasia in obese postmenopausal women." | 5.11 | Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women. ( Agorastos, T; Bontis, JN; Efstathiadis, E; Pantazis, K; Vaitsi, V; Vavilis, D, 2005) |
| "We determined gonadotropin-, estradiol- and anastrozole- serum concentrations from postmenopausal, early stage breast cancer patients receiving upfront anastrozole within routine after care." | 3.85 | Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole? ( Beer, B; Czech, T; Daniaux, M; Holzner, B; Hubalek, M; Kemmler, G; Meraner, V; Oberacher, H; Oberguggenberger, A; Sperner-Unterweger, B; Sztankay, M; Weigel, G; Wildt, L, 2017) |
| "Estradiol concentrations in postmenopausal women with early, ER-positive breast cancer on anastrozole were significantly different in normal weight versus overweight or obese patients at baseline, but not at 12 and 24 months." | 3.80 | Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole. ( Bauer, T; Hadji, P; Hars, O; Knöll, D; Kyvernitakis, I; Struck, M, 2014) |
| "A total of 216 postmenopausal patients with early-stage breast cancer who were receiving AI treatment with anastrozole constituted the final sample included in the analysis." | 3.80 | Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels. ( Beer, B; Giesinger, J; Holzner, B; Hubalek, M; Kemmler, G; Meraner, V; Oberacher, H; Oberguggenberger, A; Schubert, B; Seeber, B; Sperner-Unterweger, B; Sztankay, M; Wildt, L, 2014) |
| "Obesity has been associated with an adverse prognosis and reduced efficacy of endocrine therapy in patients with hormone receptor-positive (HR+) breast cancer (BC)." | 3.30 | The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer. ( de Graaf, H; de Roos, WK; Erdkamp, FLG; Geurts, SME; Honkoop, AH; Imholz, ALT; Kroep, JR; Lammers, SWM; Linn, SC; Smidt, ML; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van der Sangen, MJC; van Hellemond, IEG; Vriens, IJH, 2023) |
| "Obesity is associated with an increased body aromatisation and may be a cause of insufficient estradiol depletion." | 1.39 | Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer. ( Dressel-Ban, G; Dubsky, P; Exner, R; Fitzal, F; Gnant, M; Hadji, P; Königsberg, R; Maroske, M; Pfeiler, G; Seifert, M; Singer, C; Zellinger, J, 2013) |
| "Body weight were significantly increased in mice fed with a high-fat diet compared to normal diet (P<." | 1.38 | [The effect of diet induced obesity on testicular tissue and serum oxidative stress parameters]. ( Atilgan, D; Boztepe, O; Erdemir, F; Markoc, F; Sahin, S; Suha-Parlaktas, B, 2012) |
| "Hormonal therapy for endometrial cancer is occasionally warranted in the premenopausal woman who is interested in maintaining fertility." | 1.32 | Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy. ( Amezcua, C; Bahador, A; Burnett, AF, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Lammers, SWM | 1 |
| Geurts, SME | 1 |
| van Hellemond, IEG | 1 |
| Swinkels, ACP | 1 |
| Smorenburg, CH | 1 |
| van der Sangen, MJC | 1 |
| Kroep, JR | 1 |
| de Graaf, H | 1 |
| Honkoop, AH | 1 |
| Erdkamp, FLG | 1 |
| de Roos, WK | 1 |
| Linn, SC | 1 |
| Imholz, ALT | 1 |
| Smidt, ML | 1 |
| Vriens, IJH | 1 |
| Tjan-Heijnen, VCG | 1 |
| Oberguggenberger, A | 2 |
| Meraner, V | 2 |
| Sztankay, M | 2 |
| Beer, B | 2 |
| Weigel, G | 1 |
| Oberacher, H | 2 |
| Kemmler, G | 2 |
| Czech, T | 1 |
| Holzner, B | 2 |
| Wildt, L | 2 |
| Sperner-Unterweger, B | 2 |
| Daniaux, M | 1 |
| Hubalek, M | 2 |
| Morgan, MM | 1 |
| Arendt, LM | 1 |
| Alarid, ET | 1 |
| Beebe, DJ | 1 |
| Johnson, BP | 1 |
| Gnant, M | 2 |
| Pfeiler, G | 2 |
| Stöger, H | 1 |
| Mlineritsch, B | 1 |
| Fitzal, F | 2 |
| Balic, M | 1 |
| Kwasny, W | 1 |
| Seifert, M | 2 |
| Stierer, M | 1 |
| Dubsky, P | 2 |
| Greil, R | 1 |
| Steger, G | 1 |
| Samonigg, H | 1 |
| Fesl, C | 1 |
| Jakesz, R | 1 |
| Königsberg, R | 1 |
| Hadji, P | 2 |
| Maroske, M | 1 |
| Dressel-Ban, G | 1 |
| Zellinger, J | 1 |
| Exner, R | 1 |
| Singer, C | 1 |
| Kyvernitakis, I | 1 |
| Knöll, D | 1 |
| Struck, M | 1 |
| Hars, O | 1 |
| Bauer, T | 1 |
| Juang, PS | 1 |
| Peng, S | 1 |
| Allehmazedeh, K | 1 |
| Shah, A | 1 |
| Coviello, AD | 1 |
| Herbst, KL | 1 |
| Schubert, B | 1 |
| Seeber, B | 1 |
| Giesinger, J | 1 |
| Goodwin, PJ | 1 |
| Pritchard, KI | 1 |
| Erdemir, F | 1 |
| Atilgan, D | 1 |
| Markoc, F | 1 |
| Boztepe, O | 1 |
| Suha-Parlaktas, B | 1 |
| Sahin, S | 1 |
| Koloszar, S | 1 |
| Pal, Z | 1 |
| Kereszturi, A | 1 |
| Vajda, G | 1 |
| Pal, A | 1 |
| Daru, J | 1 |
| Burnett, AF | 1 |
| Bahador, A | 1 |
| Amezcua, C | 1 |
| Agorastos, T | 1 |
| Vaitsi, V | 1 |
| Pantazis, K | 1 |
| Efstathiadis, E | 1 |
| Vavilis, D | 1 |
| Bontis, JN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Open, Comparative Multicentre Trial of 3 Years Anastrozole Treatment vs. 3 Years no Treatment in Postmenopausal Patients With Breast Cancer Who Have Completed 5 Years Adjuvant Hormone Therapy.[NCT00300508] | Phase 3 | 856 participants | Interventional | 1996-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for anastrozole and Obesity
| Article | Year |
|---|---|
The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer.
Topics: Anastrozole; Body Mass Index; Breast Neoplasms; Female; Humans; Obesity; Overweight; Prognosis | 2023 |
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
Topics: Adolescent; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Ind | 2013 |
Testosterone with dutasteride, but not anastrazole, improves insulin sensitivity in young obese men: a randomized controlled trial.
Topics: 5-alpha Reductase Inhibitors; Absorptiometry, Photon; Adult; Anastrozole; Azasteroids; Body Composit | 2014 |
Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Body Mass Index; Endometrial Hyperplasia; Endometrium; Fema | 2005 |
9 other studies available for anastrozole and Obesity
| Article | Year |
|---|---|
Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Biomarkers; Body Mass Index; Breast Neop | 2017 |
Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model.
Topics: Adipocytes; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Prol | 2019 |
Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estra | 2013 |
Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Body Mass Index; Bone and Bones; Breast Neoplasms; Collagen Type | 2014 |
Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
Topics: Aged; Aged, 80 and over; Anastrozole; Androgens; Aromatase Inhibitors; Body Mass Index; Breast Neopl | 2014 |
Obesity and hormone therapy in breast cancer: an unfinished puzzle.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antag | 2010 |
[The effect of diet induced obesity on testicular tissue and serum oxidative stress parameters].
Topics: Anastrozole; Animals; Aromatase Inhibitors; Biomarkers; Body Weight; Catalase; Diet, High-Fat; Gluta | 2012 |
Effects of aromatase inhibitor on menopausal hyperplasia in a case of obesity.
Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Atrophy; Endometrial Hyperplasia; End | 2012 |
Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Endometria | 2004 |